

**DRIEHAUS CAPITAL MANAGEMENT LLC**Driehaus Event Driven Fund Portfolio  
as of 5/31/2018**Security Name**

ACLARIS THERAPEUTICS	COM
ADVERUM BIOTECH INC	
ALTICE NV	EUR0.01 (COMMON SHAR
ALTICE USA INC	CL A
ALTICE USA INC	CL A - WHEN ISSUED
ARRAY BIOPHARMA INC	COM
ATARA BIOTHERAPEUTIC	COM
AVAYA HLDGS CORP	COM
BLUEPRINT MEDICINES	COM
BUILDERS FIRSTSOURCE	COM
CLEMENTIA PHARMACEUT	COM
CONCERT PHARMACEUTIC	COM
CONSOLIDATED COMMUNI	6.5000% 10/01/22
EUR FORWARD	CONTRACT08/09/2018
EUR FORWARD	CONTRACT 8/9/2018
FGL HOLDINGS	
GENERAL MTRS CORP	DEB SR CV C ESCROW
GENERAL MTRS CORP	DEB SR CONV B ESCROW
GETTY IMAGES	BANK LOAN 10/18/2019
GETTY IMAGES INC	7.00% 10/15/2020
GOLDEN ENTERTAINMEN	TERM LOAN 10/20/2025
HC2 HLDGS INC	11.0000% 12/01/19
HC2 HOLDINGS INC	
HUNTSMAN CORP	
IDEAYA BIOSCIENCES,	INC. PRIVATE EQUITY
INSPIRE MED SYS INC	COM
ISHARES NASDAQ	BIOTECHNOLOGY ETF
KNIGHT SWIFT	TRANSPORTATION HLD
LOXO ONCOLOGY INC	COM
MARVELL TECHNOLOGY	GROUP LTD
MIRATI THERAPEUTICS	COM
MON 07/20/18 C120	MONSANTO CO NEW
MON 07/20/18 C125	MONSANTO CO NEW
MON 07/20/18 P105	MONSANTO CO NEW
NATERA INC	COM
OCEANFIRST FINL CORP	COM
ORITANI FINANCIAL	CORP
QUANTA SERVICES INC	
RENT A CTR INC NEW	4.7500% 05/01/21
ROCKWELL COLLINS	INC.
SIENTRA INC	COM
SIERRA ONCOLOGY INC	COM
SPDR S&P REGIONAL	BANKING ETF
SPDR SERIES TRUST	S&P BIOTECH
USB REALTY CORP	VAR RT PERPETUAL
UTX 01/18/19 C135	UNITED TECHNOLOGIES
WATERSTONE FINANCIAL	COM

Source: Driehaus Capital Management LLC

The portfolio represents holdings for the Driehaus Event Driven Fund (the "Fund") as of the specified date. The Fund assumes no obligation to update or supplement the holdings to reflect subsequent changes. The holdings posted may not represent current or future portfolio composition or holdings and are subject to change without notice. Information on particular holdings may be withheld if it is in the Fund's best interest to do so. The holdings are unaudited and are provided for general information on the Fund. For more information please contact us at 877-779-0079. For information regarding the Fund's policy for valuation of investments and other significant accounting policies, please refer to the Fund's recent Semi-Annual or Annual financial statements.